Soy and soy isoflavones in prostate cancer: a systematic review and meta-analysis of randomized controlled trials

2014 ◽  
Vol 113 (5b) ◽  
pp. E119-E130 ◽  
Author(s):  
M. Diana van Die ◽  
Kerry M. Bone ◽  
Scott G. Williams ◽  
Marie V. Pirotta
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Randomized Controlled Trials ◽  
Meta Analysis ◽  
Soy Isoflavones ◽  
Controlled Trials ◽  
Randomized Controlled

P3-615: EFFECTS OF SOY ISOFLAVONES ON COGNITIVE FUNCTION: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

2006 ◽  
Vol 14 (7S_Part_25) ◽  
pp. P1365-P1366
Author(s):  
Chendi Cui ◽  
Rahel Birru ◽  
Beth E. Snitz ◽  
Masafumi Ihara ◽  
Brian J. Lopresti ◽  
...  
Keyword(s):  
Systematic Review ◽  
Cognitive Function ◽  
Randomized Controlled Trials ◽  
Meta Analysis ◽  
Soy Isoflavones ◽  
Controlled Trials ◽  
Randomized Controlled

scholarly journals 177Lu-PSMA Radioligand Therapy Is Favorable as Third-Line Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials

Biomedicines ◽  
2021 ◽  
Vol 9 (8) ◽  
pp. 1042
Author(s):  
Finn E. von Eyben ◽  
Kalevi Kairemo ◽  
Channing Paller ◽  
Manuela Andrea Hoffmann ◽  
Giovanni Paganelli ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Randomized Controlled Trials ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Castration Resistant Prostate Cancer ◽  
Radioligand Therapy ◽  
Randomized Controlled ◽  
Castration Resistant ◽  
Third Line

In this systematic review and network meta-analysis (NMA), we aimed to assess the benefits and harms of third-line (L3) treatments in randomized controlled trials (RCTs) of patients with metastatic castration-resistant prostate cancer (mCRPC). Two reviewers searched for publications from 1 January 2006 to 30 June 2021. The review analyzed seven RCTs that included 3958 patients and eight treatments. Treatment with prostate-specific membrane antigen (PSMA)-based radioligand therapy (PRLT) resulted in a 1.3-times-higher rate of median PSA decline ≥50% than treatment with abiraterone, enzalutamide, mitoxantrone, or cabazitaxel (p = 0.00001). The likelihood was 97.6% for PRLT to bring about the best PSA response, out of the examined treatments. PRLT resulted in a 1.1-times-higher six-month rate of median radiographic progression-free survival. Treatment with PRLT in the VISION trial resulted in 1.05-times-higher twelve-month median overall survival than L3 treatment with cabazitaxel in other RCTs. PRLT more often resulted in severe thrombocytopenia and less often in severe leukopenia than did cabazitaxel. In conclusion, for patients with mCRPC, L3 treatment with PRLT is highly effective and safe.

scholarly journals Effects of soy isoflavones on cognitive function: a systematic review and meta-analysis of randomized controlled trials

2019 ◽  
Vol 78 (2) ◽  
pp. 134-144 ◽  
Author(s):  
Chendi Cui ◽  
Rahel L Birru ◽  
Beth E Snitz ◽  
Masafumi Ihara ◽  
Chikage Kakuta ◽  
...  
Keyword(s):  
Systematic Review ◽  
Cognitive Function ◽  
Randomized Controlled Trials ◽  
Data Extraction ◽  
Meta Analysis ◽  
Soy Isoflavones ◽  
Cochrane Library ◽  
Controlled Trials ◽  
Randomized Controlled ◽  
Design Characteristics

Abstract Context The results of preclinical and observational studies support the beneficial effect of soy isoflavones on cognition. Objective This review aimed to evaluate the effects of soy isoflavones on cognition in adults. Data Sources The PUBMED, EMBASE, Ovid Medline, Cochrane Library, and clinicaltrials.gov databases were searched. Study Selection Two researchers independently screened 1955 records, using the PICOS criteria: participants were adults; intervention was dietary sources with soy isoflavones or isolated soy isoflavones; comparator was any comparator; outcome was cognitive function; study type was randomized controlled trials (RCTs). A third researcher was consulted to resolve any discrepancies. Sixteen RCTs were included and their quality assessed. Data Extraction Information on study design, characteristics of participants, and outcomes was extracted. PRISMA guidelines were followed. Data Analysis A random-effects meta-analysis was used to pool estimates across studies. In the 16 RCTs (1386 participants, mean age = 60 y), soy isoflavones were found to improve overall cognitive function (standardized mean difference [SMD], 0.19; 95% confidence interval [CI], 0.07–0.32) and memory (SMD, 0.15; 95%CI, 0.03–0.26). Conclusion The results showed that soy isoflavones may improve cognitive function in adults. Systematic Review Registration PROSPERO registration no. CRD42018082070.

Sign in / Sign up

Export Citation Format

Share Document